265 related articles for article (PubMed ID: 18258586)
1. Alteplase for the management of occluded central venous access devices: safety considerations.
Smith LH
Clin J Oncol Nurs; 2008 Feb; 12(1):155-7. PubMed ID: 18258586
[No Abstract] [Full Text] [Related]
2. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
3. Recombinant tissue plasminogen activator for central venous access device occlusion.
Hooke C
J Pediatr Oncol Nurs; 2000 Jul; 17(3):174-8. PubMed ID: 10944865
[TBL] [Abstract][Full Text] [Related]
4. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Jacobs BR; Haygood M; Hingl J
J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
[TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
6. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
Moll S; Kenyon P; Bertoli L; De Maio J; Homesley H; Deitcher SR
J Clin Oncol; 2006 Jul; 24(19):3056-60. PubMed ID: 16809729
[TBL] [Abstract][Full Text] [Related]
8. Nurse's guide to understanding and treating thrombotic occlusion of central venous access devices.
McKnight S
Medsurg Nurs; 2004 Dec; 13(6):377-82. PubMed ID: 15714740
[TBL] [Abstract][Full Text] [Related]
9. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
Jonker MA; Osterby KR; Vermeulen LC; Kleppin SM; Kudsk KA
JPEN J Parenter Enteral Nutr; 2010; 34(4):444-9. PubMed ID: 20631392
[TBL] [Abstract][Full Text] [Related]
10. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of local instillation of recombinant tissue plasminogen activator for restoring occluded central venous catheters in neonates.
Soylu H; Brandão LR; Lee KS
J Pediatr; 2010 Feb; 156(2):197-201.e1. PubMed ID: 19969306
[TBL] [Abstract][Full Text] [Related]
12. Reducing central line-related bloodstream infections.
Clancy CM
AORN J; 2009 Jun; 89(6):1123-5. PubMed ID: 19500702
[No Abstract] [Full Text] [Related]
13. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
[TBL] [Abstract][Full Text] [Related]
14. Tackling the Achilles' heel of hemodialysis.
Winkelmayer WC
N Engl J Med; 2011 Jan; 364(4):372-4. PubMed ID: 21268730
[No Abstract] [Full Text] [Related]
15. Alteplase licensed for catheter clearance.
Thompson CA
Am J Health Syst Pharm; 2001 Nov; 58(21):2011, 2014. PubMed ID: 11715818
[No Abstract] [Full Text] [Related]
16. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
[TBL] [Abstract][Full Text] [Related]
18. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients.
Ng R; Li X; Tu T; Semba CP
J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):45-9. PubMed ID: 14709686
[TBL] [Abstract][Full Text] [Related]
19. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
Terrill KR; Lemons RS; Goldsby RE
J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
[TBL] [Abstract][Full Text] [Related]
20. Interventions for restoring patency of occluded central venous catheter lumens (Review).
van Miert C; Hill R; Jones L
Evid Based Child Health; 2013 Mar; 8(2):695–749. PubMed ID: 24482900
[No Abstract] [Full Text] [Related]
[Next] [New Search]
